Other
No prophylaxis
No prophylaxis is an intervention with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_3
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
NCT02021006
completed
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
NCT03528941
completedphase_4
Antibiotic Prophylaxis for Clean Intermittent Catheterisation
NCT02145338
Clinical Trials (3)
Showing 3 of 3 trials
NCT02021006Phase 3
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
NCT03528941
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
NCT02145338Phase 4
Antibiotic Prophylaxis for Clean Intermittent Catheterisation
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3